List of Excipients in Branded Drug PROPRANOLOL HCL ER

« Back to Dashboard

Generic Drugs Containing PROPRANOLOL HCL ER

Company	Ingredient	NDC	Excipient
Direct Rx	propranolol hcl er	61919-794	AMMONIA
Direct Rx	propranolol hcl er	61919-794	DIETHYL PHTHALATE
Direct Rx	propranolol hcl er	61919-794	ETHYLCELLULOSE
Direct Rx	propranolol hcl er	61919-794	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in PROPRANOLOL HCL ER?

# Of NDCs	Excipient
1	AMMONIA
1	DIETHYL PHTHALATE
1	ETHYLCELLULOSE
1	FERROSOFERRIC OXIDE

Propranolol HCl ER Excipient Strategy and Commercial Opportunities

Last updated: October 1, 2026

Propranolol hydrochloride extended-release products are mature oral medicines with limited active-ingredient differentiation. Commercial value is concentrated in release-control technology, capsule performance, sprinkle administration, excipient substitution, manufacturing efficiency, and differentiated regulatory positioning.

The strongest opportunity is a multiparticulate extended-release capsule that maintains once-daily exposure, resists alcohol-induced dose dumping, supports capsule opening or sprinkling, and uses broadly accepted excipients. Propranolol HCl is highly soluble and extensively metabolized, so the formulation challenge is controlled release rather than solubilization.

What is the formulation profile of propranolol HCl ER?

Propranolol hydrochloride is a nonselective beta-adrenergic receptor blocker used in cardiovascular disorders, migraine prevention, essential tremor, and other conditions. Immediate-release propranolol has a relatively short elimination half-life, generally about three to six hours, and undergoes substantial hepatic first-pass metabolism. Extended-release products are designed for once-daily administration.[1]

Attribute	Formulation implication
Active ingredient	Propranolol hydrochloride
Dosage form	Extended-release oral capsule
Common strengths	60 mg, 80 mg, 120 mg, and 160 mg
Primary release objective	Prolonged delivery over approximately 24 hours
Solubility profile	High aqueous solubility; excessive solubility can accelerate release
Main pharmacokinetic issue	Short half-life and substantial first-pass metabolism
Core development risk	Maintaining in-vitro and in-vivo release consistency
Commercial reference	Inderal LA and approved generic equivalents
Regulatory pathway	Abbreviated New Drug Application for generics; 505(b)(2) may support differentiated products

The formulation does not need a sophisticated solubilizer. It needs a reliable barrier against rapid dissolution. That favors coated pellets, matrix particles, or a combination of immediate-release and controlled-release populations.

What excipients are used in propranolol HCl ER products?

Public product labeling identifies inactive ingredients by product, and the exact composition can differ among manufacturers. Common excipient classes for propranolol HCl ER capsules include release-control polymers, pellet substrates, binders, glidants, lubricants, capsule-shell materials, and colorants.[2,3]

Release-controlling polymers

Ethylcellulose is a commercially established water-insoluble coating polymer for multiparticulate extended-release systems. It can be applied as a film around drug-loaded cores or pellets. Release is adjusted through coating weight gain, pore formation, polymer grade, and curing conditions.

Hypromellose can function as a hydrophilic matrix former, binder, or coating component. It hydrates on contact with gastrointestinal fluid and creates a diffusion pathway. In a multiparticulate system, hypromellose may be used to moderate the release profile or improve coating integrity.

Other potential polymers include ammonio methacrylate copolymers, polyvinyl acetate-based systems, cellulose acetate derivatives, and combinations of hydrophilic and hydrophobic polymers. Any substitution must be assessed against dissolution similarity, alcohol robustness, manufacturing reproducibility, and inactive-ingredient precedent.

Pellet and core materials

Sugar spheres are commonly used as inert starter cores for drug-layered pellets. Microcrystalline cellulose can support extrusion-spheronization or serve as a diluent in matrix pellets. Povidone and hypromellose may improve adhesion between propranolol HCl and the core.

A pellet system creates a larger surface area than a monolithic tablet. That supports smoother dose release and can reduce the impact of localized manufacturing defects. It also allows the capsule to contain multiple release populations.

Lubricants, glidants, and processing aids

Talc, colloidal silicon dioxide, magnesium stearate, and related excipients may be used to improve powder flow, reduce sticking, and support capsule filling. Their levels must remain low enough to avoid changes in wetting, coating adhesion, and dissolution.

High lubricant concentration can delay wetting and produce lot-to-lot dissolution shifts. This issue is material for propranolol because the drug dissolves rapidly once exposed to aqueous media.

Capsule-shell excipients

Hard gelatin capsules are conventional for the category. Titanium dioxide, iron oxides, and approved colorants may be used for identification and light protection. Hypromellose capsules provide a potential gelatin-free option, although shell substitution requires assessment of moisture transfer, brittleness, dissolution, fill-weight performance, and stability.

How should an excipient strategy be designed for propranolol ER?

A practical strategy starts with a multiparticulate platform rather than a simple hydrophilic matrix capsule.

Preferred platform: coated drug-loaded pellets

A coated-pellet system can use the following architecture:

1. Inert or matrix-forming core.
2. Propranolol HCl drug layer.
3. Seal coat or protective subcoat.
4. Rate-controlling polymer film.
5. Optional overcoat for handling and capsule-fill performance.

The critical control variables are polymer type, polymer weight gain, plasticizer level, pore former, coating uniformity, pellet size distribution, and curing conditions. The development target should be a dissolution profile that remains stable across pH conditions and agitation rates.

Dual-population release design

A commercially differentiated product could combine:

• An immediate-release fraction for early therapeutic exposure.
• A controlled-release fraction for maintenance over the dosing interval.

This design could improve the initial concentration profile while preserving once-daily administration. It may also permit more flexible matching to the reference product than a single uniform pellet population.

The development burden is higher because the sponsor must control the ratio between release populations and demonstrate batch uniformity. The design is most attractive where the product can obtain a clinically meaningful pharmacokinetic or administration advantage.

Alcohol dose-dumping resistance

Alcohol robustness is a major formulation screen for modified-release products. Ethanol can plasticize some polymers, increase drug permeability, or disrupt coating films. A robust system should be tested in media containing relevant ethanol concentrations and under conditions that expose failure modes.

Ethylcellulose-based systems can be engineered for resistance, but performance depends on polymer grade, plasticizer, pore-former selection, coating thickness, and curing. Alcohol testing should be integrated early rather than treated as a late-stage quality exercise.

Sprinkle and capsule-opening performance

A sprinkle-compatible capsule could improve administration for patients who have difficulty swallowing. The development target is delivery of the intact multiparticulate contents onto soft food or into a suitable liquid without crushing, chewing, or dose segregation.

Key tests include:

• Content uniformity after capsule opening.
• Pellet recovery from food or liquid.
• Stability during the labeled administration window.
• Retention of extended-release performance.
• Absence of unacceptable taste or mouthfeel.
• Resistance to crushing and chewing.

This feature can create commercial separation in a genericized market, particularly for pediatric, geriatric, and dysphagia populations.

What excipient substitutions offer the strongest commercial opportunity?

Excipient substitutions are most valuable when they address supply risk, manufacturing cost, patient acceptability, or regulatory restrictions.

Opportunity	Candidate strategy	Commercial value	Main risk
Gelatin-free capsule	Hypromellose shell	Moderate	Moisture transfer and shell-performance changes
Improved pellet robustness	Optimized seal coat and binder	Moderate	More process steps
Alcohol resistance	Hydrophobic polymer blend	High	Dissolution failure or bioequivalence risk
Sprinkle administration	Multiparticulate capsule contents	High	Taste, segregation, and labeling requirements
Lower-cost manufacture	Higher-solids coating or continuous coating	Moderate to high	Scale-up and content uniformity
Reduced colorant burden	Simplified capsule shell	Low to moderate	Product identification and branding
Improved supply resilience	Multi-source polymers and core excipients	Moderate	Bridging and qualification work
Pediatric positioning	Smaller capsules or flexible dose contents	High	Dose accuracy and clinical positioning

An excipient change is not commercially meaningful by itself. It becomes valuable when it improves the product's regulatory pathway, cost structure, patient use, or supply reliability.

What FDA regulatory requirements apply to propranolol HCl ER excipients?

A generic propranolol HCl ER product generally requires an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug. The sponsor must match the reference product's dosage form, strength, route, and release characteristics unless an approved difference is supported under FDA requirements.[4]

Inactive Ingredient Database and prior precedent

FDA's Inactive Ingredient Database provides precedent for excipient use by route and dosage form. It does not automatically authorize a new formulation. The sponsor must evaluate maximum daily exposure, functional role, route-specific safety, and dosage-form precedent.[5]

For a modified-release capsule, the regulatory package should address:

• Quantitative composition.
• Excipient specifications.
• Functional performance and critical material attributes.
• Dissolution method and acceptance criteria.
• Comparative dissolution against the reference product.
• Alcohol dose-dumping behavior.
• Stability under long-term and accelerated conditions.
• Manufacturing process validation.
• Bioequivalence and pharmacokinetic comparability.
• Capsule-opening or sprinkle performance if included in labeling.

A formulation with novel excipients or materially higher excipient exposure can create additional FDA review risk. Established excipients with oral modified-release precedent generally provide a cleaner pathway.

How strong is the patent estate for propranolol HCl ER?

Propranolol HCl and the original extended-release concept are mature technologies. Core composition-of-matter and early formulation patents are generally no longer the principal barrier to generic entry. Remaining patent value is more likely to reside in narrow formulation claims, specific coating systems, manufacturing processes, particle architectures, or differentiated administration methods.

Patent category	Likely status for a mature propranolol ER product	Strategic relevance
Propranolol compound patent	Expired or commercially obsolete	Minimal
Basic ER dosage form	Likely expired or weak against modern alternatives	Low
Specific pellet or coating composition	May remain relevant if separately patented	Moderate
Manufacturing process	Potentially enforceable if claim scope is narrow	Moderate
Sprinkle formulation	Potential differentiation if claims remain active	Moderate
Pediatric or disease-specific method	Possible but dependent on claim and regulatory listing	Low to moderate
Trade secret process parameters	Often more important than patents	High

Orange Book listings, patent expiration dates, and Paragraph IV certifications must be checked product by product. A generic sponsor cannot assume that the absence of a broad foundational patent means every formulation is unrestricted. Conversely, narrow claims may not prevent a non-infringing alternative formulation.[4,6]

When does propranolol HCl ER lose exclusivity?

The category has already moved into a genericized phase. Inderal LA is an established reference product, and propranolol HCl ER capsules are marketed by multiple generic manufacturers. The key commercial issue is therefore not initial loss of exclusivity but the ability to obtain durable margin through formulation differentiation.

FDA regulatory exclusivity and patent protection are distinct. A product may have no remaining meaningful market exclusivity while still presenting product-specific patent or regulatory issues. An ANDA applicant must evaluate the current Orange Book record, listed patents, certifications, and any litigation history for the relevant reference product.[4]

Which companies compete in propranolol HCl ER?

Competition is divided among the reference product holder, established generic manufacturers, contract manufacturers, and potential 505(b)(2) developers.

Reference and generic competition

Inderal LA established the once-daily extended-release category. Generic propranolol HCl ER products compete primarily on:

• Wholesale acquisition cost.
• Supply reliability.
• Number of approved strengths.
• Distributor and group-purchasing access.
• FDA inspection history.
• Formulary status.
• Capsule-opening and administration features.
• Ability to support hospital and institutional purchasing.

The market is vulnerable to price compression because the active ingredient is inexpensive and multiple excipients have established commercial sources. Shortages or manufacturing interruptions can temporarily increase the value of reliable supply.

505(b)(2) opportunities

A 505(b)(2) product could pursue a differentiated profile rather than a conventional ANDA strategy. Potential concepts include:

• Improved sprinkle administration.
• Pediatric dose flexibility.
• Reduced capsule size.
• Modified release designed for a defined exposure profile.
• Combination of immediate-release and extended-release fractions.
• Gelatin-free or otherwise differentiated capsule presentation.
• Product designed for patients with swallowing limitations.

The commercial case is strongest when the formulation solves a documented administration problem and supports a defensible label, rather than offering an imperceptible excipient change.

What manufacturing and intellectual-property barriers matter most?

The highest barriers are process reproducibility and dissolution control.

Multiparticulate systems require consistent pellet size, drug loading, coating thickness, moisture content, and capsule fill weight. Small process deviations can shift the release profile. Scale-up from laboratory fluid-bed coating to commercial equipment can alter spray rate, atomization, drying, agglomeration, and coating uniformity.

Manufacturing controls should focus on:

• Particle-size distribution.
• Drug-layer uniformity.
• Polymer weight gain.
• Residual solvent and moisture.
• Coating defects.
• Pellet friability.
• Blend segregation.
• Capsule-fill accuracy.
• Dissolution at multiple sampling points.
• Stability after packaging.

Trade secrets may provide stronger practical protection than patents when they cover coating parameters, curing conditions, equipment configuration, and in-process controls. A freedom-to-operate review should cover composition claims, coating claims, capsule-content claims, manufacturing claims, and any patents listed for the reference product.

What are the generic launch and revenue opportunities?

A conventional generic launch is likely to face price erosion and limited brand loyalty. The strongest opportunities are targeted products with one or more measurable advantages.

Product concept	Likely market position	Revenue potential
Standard AB-rated capsule	Commodity generic	Low to moderate
Multi-strength generic with dependable supply	Institutional and retail supply product	Moderate
Sprinkle-compatible ER capsule	Differentiated generic or 505(b)(2)	Moderate to high
Alcohol-resistant multiparticulate product	Regulatory and quality differentiation	Moderate
Pediatric-focused presentation	Specialty or niche product	Moderate
Gelatin-free product	Patient and institutional preference segment	Low to moderate
Novel once-daily exposure profile	Potential branded reformulation	High, but development risk is high

Revenue exposure depends on market share, net price, reimbursement, and the number of competing ANDA holders. Public sales figures for individual generic propranolol HCl ER products are often unavailable because manufacturers report sales at broader portfolio levels. The commercial model should therefore use scenario-based assumptions rather than reference-product revenue as a direct proxy.

How does propranolol HCl ER compare with other extended-release beta blockers?

Product category	Formulation challenge	Differentiation opportunity
Propranolol HCl ER	High solubility and short half-life	Multiparticulate release, sprinkle use, exposure control
Metoprolol succinate ER	Dose-dependent release and tablet matrix behavior	Tablet technology and dose flexibility
Atenolol	Hydrophilic active with renal elimination	Less formulation complexity, lower premium potential
Carvedilol CR	Complex absorption and formulation profile	Larger opportunity for formulation engineering
Nadolol	Long half-life relative to propranolol	Lower need for aggressive extended release

Propranolol has a stronger formulation rationale than beta blockers with naturally longer half-lives. Its high solubility also creates a more demanding release-control problem than poorly soluble drugs, where dissolution can provide part of the sustained-release effect.

Key Takeaways

• Propranolol HCl ER is a mature, genericized market with limited value in ordinary excipient substitution.
• Multiparticulate coated pellets are the most defensible platform for controlled release, sprinkle administration, and alcohol robustness.
• Ethylcellulose, hypromellose, microcrystalline cellulose, povidone, talc, and capsule-shell materials are relevant excipient classes, but exact composition varies by manufacturer.
• Commercial differentiation is strongest in sprinkle performance, pediatric usability, manufacturing reliability, alcohol resistance, and gelatin-free presentation.
• FDA strategy should prioritize established oral modified-release excipients and demonstrate comparative dissolution, pharmacokinetic equivalence, stability, and dose-dumping resistance.
• Foundational propranolol and early extended-release patent barriers are mature. Current freedom-to-operate risk is more likely to arise from narrow formulation, process, or administration claims.
• A conventional ANDA can provide volume but is exposed to price erosion. A differentiated 505(b)(2) or specialty generic product offers greater margin potential but requires a clear clinical or administration benefit.

FAQs

Can propranolol HCl ER be formulated as a tablet instead of a capsule?

Yes. A tablet, matrix system, or tablet-in-capsule configuration is technically possible. The sponsor must establish comparable release, bioequivalence, stability, manufacturability, and product performance against the applicable reference product.

Which excipient is best for controlling propranolol release?

No single excipient is universally best. Ethylcellulose is a common starting point for hydrophobic film control, while hypromellose supports hydrophilic matrix or coating systems. The optimal selection depends on target release, alcohol performance, coating process, and regulatory precedent.

Is a sprinkle formulation commercially attractive for propranolol ER?

Yes, if it preserves extended-release performance after capsule opening and provides accurate delivery without chewing. The opportunity is strongest for pediatric, geriatric, and dysphagia populations.

Does propranolol HCl ER require a novel excipient?

Usually no. Established oral excipients can support development. A novel excipient may increase regulatory burden and is unlikely to be justified unless it provides a material manufacturing or performance advantage.

What is the main technical failure mode in propranolol ER development?

The principal failure mode is an unacceptable dissolution profile caused by coating variability, rapid release under alcohol exposure, pellet damage during processing, or changes in wetting and polymer permeability during stability.

References

1. U.S. Food and Drug Administration. (2023). Inderal LA (propranolol hydrochloride) extended-release capsules: Prescribing information.
2. DailyMed. (2024). Propranolol hydrochloride extended-release capsules: Product labeling and inactive ingredients. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024). Propranolol hydrochloride extended-release capsules: Approved product labeling.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
6. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.